Search - tctmd.com

Displaying 61 - 80 of 830

Sort: Relevancy | Date

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

News Conference News AHA 2024

Lipid Fluctuations Over Time May Portend Dementia: ASPREE

Yael L. Maxwell

November 15, 2024

News Daily News

Rural Counties Bore Brunt of Worsening CV Mortality During Pandemic

Yael L. Maxwell

November 15, 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

News Features

Can ‘Body Roundness Index’ Replace BMI? That Depends, Say Experts

Michael O'Riordan

October 21, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Daily News

Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome

Caitlin E. Cox

October 04, 2024

News Daily News

Cramming Weekly Physical Activity Into 1 or 2 Days Still Yields Benefits

Michael O'Riordan

October 03, 2024

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Daily News

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Yael L. Maxwell

August 19, 2024

News Daily News

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

Michael O'Riordan

August 02, 2024

Advertisement

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Lipid Fluctuations Over Time May Portend Dementia: ASPREE

Rural Counties Bore Brunt of Worsening CV Mortality During Pandemic

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Can ‘Body Roundness Index’ Replace BMI? That Depends, Say Experts

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome

Cramming Weekly Physical Activity Into 1 or 2 Days Still Yields Benefits

Statins Are Cost-effective in the Elderly

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content